STOCK TITAN

Gbx International Group Inc - GBXI STOCK NEWS

Welcome to our dedicated page for Gbx International Group news (Ticker: GBXI), a resource for investors and traders seeking the latest updates and insights on Gbx International Group stock.

GBX International Group, Inc. (OTC PINK: GBXI) is a prominent player in international economic development, focusing on innovative cancer drug research and development. The company is currently raising $1 million for critical operating capital to accelerate cancer drug valuation audits, drug releases, and uplisting to NASDAQ. With a portfolio of low-cost, effective cancer-killing drugs, including the Harvard Award-Winning CSi-Harvard, GBXI aims to revolutionize cancer treatment accessibility and affordability.

-
-
Rhea-AI Summary
GBX International Group, Inc. announces completion of initial target acquisitions for new conglomerate growth model. Spinout acquisition companies include Cannabis Science, Thermic Science, and XRAYMEDIA Group. Shareholders will receive prorata shares in each spinout company. GBXI will focus on bringing new listings and trading on OTC Markets and NASDAQ. ASU Digital Business HUB will be used as main business student learning center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
-
-
Rhea-AI Summary

GBX International Group, Inc. (OTC:GBXI) announced the acquisition of American States University (ASU) by Mr. Raymond C. Dabney, who has gained majority shareholder control. This strategic move aims to enhance GBXI's operations in education, drug development, advanced technologies, and green energy. The ASU Digital Business HUB will serve as a pivotal platform to facilitate share trading for multiple partner companies, offering existing shareholders additional pro-rata shares in spinout companies. The acquisition is part of GBXI's broader aggressive growth plan to integrate ASU with its CSi-EDP partners, create job opportunities, and expand educational offerings. The initiative includes a diverse array of programs, scholarships, and apprenticeships, targeting economic development across various industries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.51%
Tags
Rhea-AI Summary

GBX International Group has completed a corporate review, revealing a stronger Balance Sheet following asset acquisition adjustments. The company identified inaccuracies in previous financial records, leading to the writing off of $3,125,090 in Notes Payable and $3,043,629 in assets—primarily due to an impairment loss. This effort aims to clarify the company's financial standing as it shifts to a new business model. GBXI aims to support local merchants with marketing solutions and affordable processing services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary

GBX International Group, Inc. (OTC PINK:GBXI) has filed a Supplemental Information report detailing its ongoing corporate review and restructuring as it shifts to a new core business model. This review, prompted by a recent asset acquisition, includes a management team overhaul and a financial audit, revealing past discrepancies in financial records. These corrections are expected to enhance the company's Balance Sheet significantly. GBXI now aims to assist local merchants and small businesses in customer acquisition and profitability through a unique marketing system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
39.78%
Tags
none
-
Rhea-AI Summary

GBX International Group, Inc. (OTC PINK:GBXI) has unveiled a new business model aimed at enhancing the profitability and customer acquisition of local merchants and small businesses. The company provides a range of marketing tools and discounted credit card processing services, leveraging both traditional and digital payment methods. Future growth strategies include expanding product offerings and pursuing potential acquisitions or joint ventures. GBXI's focus on integrating new technologies aligns with its commitment to support local businesses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
none

FAQ

What is the current stock price of Gbx International Group (GBXI)?

The current stock price of Gbx International Group (GBXI) is $0.0001 as of February 20, 2025.

What is the market cap of Gbx International Group (GBXI)?

The market cap of Gbx International Group (GBXI) is approximately 42.3K.

What is GBX International Group, Inc. (GBXI) known for?

GBXI is known for its international economic development initiatives, particularly in the field of cancer drug research and development.

What is the current financial focus of GBXI?

GBXI is currently raising $1 million for critical operating capital to accelerate cancer drug valuation audits, drug releases, and NASDAQ uplisting.

What sets GBXI's cancer-killing drugs apart?

GBXI's portfolio includes low-cost, effective cancer-killing drugs, notably the Harvard Award-Winning CSi-Harvard drug, designed to make cancer treatment more accessible and affordable.

What are GBXI's plans for the future?

GBXI aims to revolutionize cancer treatment accessibility and affordability through its groundbreaking drug portfolio, strategic partnerships, and market uplisting.

How does GBXI impact the cancer treatment landscape?

GBXI's innovative approach to cancer drug research and development has the potential to transform the cancer treatment landscape, offering cost-effective solutions and hope to patients in need.

Who leads GBX International Group, Inc.?

Raymond C. Dabney serves as the President & CEO, Chancellor of GBXI, overseeing the company's strategic direction and growth initiatives.

What is the significance of GBXI's Harvard Award-Winning drugs?

GBXI's Harvard Award-Winning drugs, particularly the CSi-Harvard drug, have the potential to significantly impact the cancer treatment market by offering effective, low-cost alternatives to existing treatments.

How does GBXI aim to raise funds for its initiatives?

GBXI is actively raising capital to support its cancer drug research and development projects, including fundraising efforts to accelerate valuation audits, drug releases, and market uplisting.

What partnerships does GBXI have in the healthcare industry?

GBXI collaborates with various stakeholders in the healthcare industry to advance its cancer drug research and development efforts, with a focus on creating innovative, cost-effective solutions for patients worldwide.

What is the long-term vision of GBX International Group, Inc.?

GBXI's long-term vision is to become a leading player in the international economic development sector, particularly in the field of cancer drug research and development, by offering groundbreaking drugs that revolutionize cancer treatment accessibility and affordability.
Gbx International Group Inc

OTC:GBXI

GBXI Rankings

GBXI Stock Data

42.26k
139.86M
Advertising Agencies
Communication Services
Link
United States
Corona